Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1Meningioma 1

Interventions

lutetium Lu 177 dotatate 2Specimen Handling 2Magnetic Resonance Spectroscopy 2pembrolizumab 1olaparib 1gallium Ga 68 dotatate 1fludarabine 1Surgical Procedures, Operative 1Semaxinib 1Radiosurgery 1Proton Therapy 1Nivolumab 1Lysine 1Ipilimumab 1Interleukin-2 1Imatinib Mesylate 1Ga(III)-DOTATOC 1Erlotinib Hydrochloride 1Cyclophosphamide 1Crossing Over, Genetic 1CTLA-4 Antigen 1Arginine 164Cu-SARTATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1177Lu-DOTA-JR11 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Meningioma × 64Cu-SARTATE × Clear all
NCT03936426 2020-04-20

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATEâ„¢

Clarity Pharmaceuticals Ltd

Phase 1/2 Completed
5 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡